FDA approved an updated version of MarginProbe

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved an updated version of MarginProbe, a medical device that enables real-time detection of cancer at the surface of excised tissue specimens during breast-conserving cancer surgery. MarginProbe is developed by Dune Medical Devices.

Surgeon feedback, design ideas and miniaturization engineering were the driving forces behind the development of MarginProbe 1.2, according to Dune. The new version uses the same diagnostic technology as version 1.1, improving functionality, portability and overall ease of use, including a smaller size and a brighter screen.

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login